Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease
Related Experiment Video
Updated: Jul 28, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Junnan Wang1, Youyou Yan1, Dandan Song2
1Department of Cardiology, Second Hospital of Jilin University, No. 218 Ziqiang Street, Changchun 130041, China.
Insights
Plasma microRNA-146a (miR-146a) levels can differentiate coronary artery disease (CAD) patients with good or poor coronary collateral circulation (CCC). Elevated miR-146a indicates good CCC, while decreased levels suggest poor CCC in CAD patients.
Area of Science:
- Cardiology
- Molecular Biology
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) patients benefit from coronary collateral circulation (CCC).
- Lack of reliable biomarkers hinders the assessment of CCC in CAD.
- MicroRNAs are implicated in cardiovascular disease pathogenesis.
Purpose of the Study:
- To investigate the relationship between plasma microRNA-146a (miR-146a) and coronary collateral circulation (CCC) in CAD patients.
- To evaluate miR-146a as a potential blood-based biomarker for CCC in CAD.
Main Methods:
- Plasma miR-146a and VEGF-A levels were measured using real-time PCR and ELISA, respectively.
- Patients were categorized based on Rentrop grading for CCC assessment.
- Correlations between miR-146a levels and Rentrop grades were analyzed.
Main Results:
- Plasma miR-146a levels were significantly higher in CAD patients with good CCC and lower in those with poor CCC.
- A positive correlation was observed between plasma miR-146a levels and Rentrop grading.
- VEGF-A showed a similar trend but without statistical significance between groups.
Conclusions:
- Plasma miR-146a is significantly associated with the degree of coronary collateral circulation in CAD patients.
- miR-146a demonstrates potential as a diagnostic biomarker for identifying poor CCC in CAD.
- Further research is warranted to validate miR-146a as a clinical tool for CCC assessment.
Abstract:
Coronary collateral circulation (CCC), an alternative blood supply for ischemic myocardium, improves survival rates among patients with coronary artery disease (CAD). However, there remains a lack of biomarkers to discriminate between patients with poor or good CCC. In this study, we aimed to observe the relationship between plasma microRNA-146a (miR-146a) levels and the coronary collateral circulation (CCC). Additionally, we aimed to explore whether the plasma miR-146a level could serve as a blood-based biomarker for CCC in patients with CAD. We measured the plasma levels of vascular endothelial growth factor A (VEGF-A) and miR-146a in patients with CCC by ELISA and real-time PCR, respectively, according to the Rentrop grades. The results showed that the plasma miR-146a level is significantly increased in CAD patients with good CCC and significantly decreased in those with poor CCC. In contrast, although VEGFA expression in patients followed a similar trend as the CCC, the differences between the groups were not statistically significant. There was a positive correlation between plasma miR-146a levels and the Rentrop grading. In addition, receiver operator characteristic analysis showed that miR-146a could be a potent biomarker for identifying patients with poor CCC.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
